(Q34291281)

English

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

26 February 2018

http://europepmc.org/abstract/PMC/5818209

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib (English)

1 reference

Europe PubMed Central

PMC publication ID

26 February 2018

http://europepmc.org/abstract/PMC/5818209

0 references

multiple myeloma

1 reference

based on heuristic

inferred from title

Andrzej Jakubowiak

4

object named as

Andrzej J Jakubowiak

1 reference

Europe PubMed Central

PMC publication ID

26 February 2018

http://europepmc.org/abstract/PMC/5818209

12

object named as

Michael Wang

1 reference

Europe PubMed Central

PMC publication ID

26 February 2018

http://europepmc.org/abstract/PMC/5818209

author name string

Ravi Vij

1

1 reference

Europe PubMed Central

PMC publication ID

26 February 2018

http://europepmc.org/abstract/PMC/5818209

David S Siegel

2

1 reference

Europe PubMed Central

PMC publication ID

26 February 2018

http://europepmc.org/abstract/PMC/5818209

Sundar Jagannath

3

1 reference

Europe PubMed Central

PMC publication ID

26 February 2018

http://europepmc.org/abstract/PMC/5818209

Alexander Keith Stewart

5

1 reference

Europe PubMed Central

PMC publication ID

26 February 2018

http://europepmc.org/abstract/PMC/5818209

Kevin McDonagh

6

1 reference

Europe PubMed Central

PMC publication ID

26 February 2018

http://europepmc.org/abstract/PMC/5818209

Nizar Bahlis

7

1 reference

Europe PubMed Central

PMC publication ID

26 February 2018

http://europepmc.org/abstract/PMC/5818209

Andrew Belch

8

1 reference

Europe PubMed Central

PMC publication ID

26 February 2018

http://europepmc.org/abstract/PMC/5818209

Lori A Kunkel

9

1 reference

Europe PubMed Central

PMC publication ID

26 February 2018

http://europepmc.org/abstract/PMC/5818209

Sandra Wear

10

1 reference

Europe PubMed Central

PMC publication ID

26 February 2018

http://europepmc.org/abstract/PMC/5818209

Alvin F Wong

11

1 reference

Europe PubMed Central

PMC publication ID

26 February 2018

http://europepmc.org/abstract/PMC/5818209

language of work or name

0 references

publication date

30 July 2012

1 reference

Europe PubMed Central

PMC publication ID

26 February 2018

http://europepmc.org/abstract/PMC/5818209

British Journal of Haematology

1 reference

Europe PubMed Central

PMC publication ID

26 February 2018

http://europepmc.org/abstract/PMC/5818209

158

1 reference

Europe PubMed Central

PMC publication ID

26 February 2018

http://europepmc.org/abstract/PMC/5818209

6

1 reference

Europe PubMed Central

PMC publication ID

26 February 2018

http://europepmc.org/abstract/PMC/5818209

739-748

1 reference

Europe PubMed Central

PMC publication ID

26 February 2018

http://europepmc.org/abstract/PMC/5818209

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5818209

6 July 2018

Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5818209

6 July 2018

Follow-up psychophysical studies in bortezomib-related chemoneuropathy patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5818209

6 July 2018

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5818209

6 July 2018

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5818209

6 July 2018

Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5818209

6 July 2018

Treatment of relapsed and refractory multiple myeloma in the era of novel agents

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5818209

6 July 2018

The evolution and impact of therapy in multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5818209

6 July 2018

Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5818209

6 July 2018

A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5818209

6 July 2018

Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5818209

6 July 2018

Pegylated liposomal Doxorubicin: a review of its use in the treatment of relapsed or refractory multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5818209

6 July 2018

The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5818209

6 July 2018

Multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5818209

6 July 2018

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5818209

6 July 2018

Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5818209

6 July 2018

International uniform response criteria for multiple myeloma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5818209

6 July 2018

International staging system for multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5818209

6 July 2018

Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5818209

6 July 2018

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5818209

6 July 2018

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5818209

6 July 2018

Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5818209

6 July 2018

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09232.X

21 January 2018

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09232.X

21 January 2018

Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09232.X

21 January 2018

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2012.09232.X

21 January 2018

Multiple myeloma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22845873

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1111/J.1365-2141.2012.09232.X

1 reference

Europe PubMed Central

PMC publication ID

26 February 2018

http://europepmc.org/abstract/PMC/5818209

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

26 February 2018

http://europepmc.org/abstract/PMC/5818209

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

26 February 2018

http://europepmc.org/abstract/PMC/5818209

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34291281&oldid=2269553222"